IDEAYA Biosciences, Inc. (30J.F)

37,20 -0,60 (-1,59%) Börsenschluss: 08:04AM CEST

IDEAYA Biosciences, Inc.

7000 Shoreline Court
Suite 350
South San Francisco, CA 94080
United States
650 443 6209
https://www.ideayabio.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 124

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Yujiro S. Hata	President, CEO & Director	846,01k	2,21M	1974
Mr. Andres Ruiz Briseno CPA	Principal Accounting Officer, Senior VP and Head of Finance & Investor Relations	450,02k	N/A	1986
Dr. Michael A. White Ph.D.	Chief Scientific Officer	613,91k	N/A	1966
Mr. Jason S. Throne Esq., J.D.	Chief Legal Officer & Company Secretary	555,47k	838,34k	1972
Dr. Darrin M. Beaupre M.D., Ph.D.	Chief Medical Officer	617,42k	N/A	1967
Dr. Paul A. Barsanti Ph.D.	Chief Technology Officer	N/A	N/A	N/A
Mr. Mick O'Quigley	Chief of Staff & Clinical Development	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in EUR.

Beschreibung

IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability. It offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Novartis International Pharmaceuticals Ltd., Amgen Inc., Gilead Sciences, Inc., Cancer Research UK, and the University of Manchester. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Corporate Governance

IDEAYA Biosciences, Inc.s ISS Governance QualityScore, Stand 1. Mai 2024, lautet 7. Die grundlegenden Scores sind Audit: 3, Vorstand: 6, Shareholderrechte: 8, Kompensation: 9.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.